TII Gears Up for Medical Contract Mfg with New Factory and R&D Unit

3xper Innoventure Ltd, launched by TII last year, is carving a niche in the fast-growing CDMO segment. With the pharmaceutical industry increasingly outsourcing R&D and manufacturing, 3xper Innoventure provides comprehensive chemistry solutions across the drug lifecycle. The venture serves global pharmaceutical, healthcare, agricultural, nutritional, and specialty chemical companies, positioning itself as a significant player in the market.

To bolster its growth, 3xper Innoventure has established a state-of-the-art R&D facility in Chennai. This facility, staffed by 50 scientists and chemists, focuses on process and analytical chemistries, scale-up, and technology transfer. The cutting-edge labs are dedicated to driving innovation and ensuring efficient drug development processes.

In addition to the R&D facility, a greenfield plant is being constructed in Naidupeta, approximately 120 km from Chennai. This plant aims to support 3xper's manufacturing ambitions, offering services from small-scale material generation to commercial-scale manufacturing. It will handle custom synthesis and the commercial production of key starting materials, intermediates, and APIs.

M A M Arunachalam, Executive Chairman of TII, highlighted the young and energetic R&D and manufacturing team driving this initiative. The completion of the Kilo lab and the ongoing construction of the pilot plant are significant milestones in building the necessary capabilities and capacities for 3xper Innoventure's success.

In FY24, TI Medical, another TII venture, recorded a revenue of ₹164 crore and a profit before tax of ₹22 crore since its acquisition. Both TI Medical and 3xper Innoventure are consolidating resources, operations, and product offerings to prepare for future growth prospects, positioning TII for continued success in the pharmaceutical industry.

News By Rahul Yelligetti